A Comparative Study of the Pharmacokinetics of SIM0718 Injection in Healthy Adult Subjects in China

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

178

Participants

Timeline

Start Date

November 28, 2024

Primary Completion Date

February 28, 2025

Study Completion Date

March 31, 2025

Conditions

Healthy Adult Subjects

Interventions

DRUG

Rademikibart injection

300 mg administered subcutaneously on the first day

DRUG

CBP-201 injection

300 mg administered subcutaneously on the first day

All Listed Sponsors

lead

Simcere Pharmaceutical Co., Ltd

OTHER

NCT06701149 - A Comparative Study of the Pharmacokinetics of SIM0718 Injection in Healthy Adult Subjects in China | Biotech Hunter | Biotech Hunter